The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Benefits of a biomarker to predict sever toxicity
Michel Obeid
• 4 Apr 2022
Michel Obeid, MD, PhD, CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses investigating a particular type of biomarker to predict and therefore avoid severe toxicity to ultimately improve a patients safety and tolerance to therapeutic agents. This interview took place during the virtual European Lung Cancer Congress 2022.
